---

Who We Are . . . .

Amarillo Biosciences, Inc., (AMAR), is a biopharmaceutical company developing low-dose oral and topical interferon alpha. We are directing our research at the treatment of Behcet's Disease and chronic cough in idiopathic pulmonary fibrosis.

Low-dose oral interferon is Fundamentally Better than from high dose injectable interferon.

In this site, we will show the fundamental differences, and how we are pressing forward with our clinical trial programs, continued research and market development.The distinct advantages and characteristics of our product and part of the fundamental differences are it's oral delivery, and safety because of the low dose. Our product dose is only 1/20,000 (one twenty thousandth) of the typical injectable dose.

We are committed to bringing low-dose oral interferon and it's many distinct advantages to a worldwide marketplace.

"Good ideas are not adopted automatically. They must be driven into practice with courageous patience."

- Hyman Rickover